Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine for Dexmedetomidine Recovery in Pediatric MRI
NCT06538584Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sedation comparing Caffeine Group with Placebo Group (2 arms). Primary endpoint: Time from end of Dex infusion to awake at 2 hours. Started Sep 2024; status: recruiting.
02
Drugs
caffeine
03
Conditions
sedation
Beyond the preview
Go deeper on NCT06538584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538584.